Professional and Scientific Career

• 1987-1994 Study of human medicine, Charité Berlin, University of Saint Petersburg
• 1994-2003 Research assistant, Charité Berlin Mitte
• 1996 Doctorate in medicine at the Charité Universitätsmedizin Berlin
• 2003 Specialist in internal medicine
• 2003-2007 Senior consultant in cardiology, Klinik am See, Rüdersdorf near Berlin, specialist clinic for internal medicine
• 2006 Specialisation in cardiology
• 06/2007 Establishment as a cardiologist in the cardiological group practice Am Park Sanssouci Potsdam
• Since 2012 External collaboration in the Endowed Professorship for Rehabilitation Sciences at the University of Potsdam
• Since 2014 Teaching at the Chair of Sports Medicine and Sports Orthopaedics; Faculty of Human Sciences at the University of Potsdam
• Since 2015 Teaching at the Chair of Rehabilitation Sciences, Faculty of Health Sciences (M.Sc. Integrative Sport, Exercise and Health Science)
• 2017 Habilitation as a private lecturer at the University of Potsdam, Department of Sport and Health Sciences
• 2022 Additional qualification in sports cardiology level 2
• 2022 Further training as a DGFF® lipidologist
• 2023 Rehabilitation at the Faculty of Health Sciences, University of Potsdam
• 2023 Appointment as adjunct professor, Faculty of Health Sciences, University of Potsdam

Research Areas

• Development of a pacemaker system with frequency control via the autonomic nervous system (Inos2, Biotronik) in co-operation with the Central Institute for Biomedical Engineering at the University of Erlangen-Nuremberg
• Effectiveness of biventricular resynchronisation in patients with cardiac insufficiency
• Rehabilitation of patients with implanted electrical devices (defibrillators) and heart failure
• Differential therapy of coronary heart disease
• Risk factor descriptors in the secondary prevention of atherosclerosis
• Cardiological care research (oral anticoagulation, pharmacology of heart failure, atrial fibrillation)
• Sports cardiological and telemedical interventions

Publications

2026

„Leitlinie klar – Umsetzung unzureichend: SGLT2i und NT-proBNP-Bestimmung zu selten eingesetzt“, DGK-Jahrestagung 2026, Herz Medizin, 04/2026: https://herzmedizin.de/fuer-aerzte-und-fachpersonal/newsroom/kardiologie-interdisziplinaer/herz-und-metabolismus/dgk-jahrestagung-2026-watch-hf-subanalyse

2025

Wassmann S , Smetak N , Luedde M , Roedicker F , Ziegler E , Celer T , Reibis R. WATCH HF Awareness of prevalence, diagnosis and treatment of chronic heart failure in at risk patients in german primary care analysing real world data of chronic HF management in Germany. European Heart Journal, Volume 46, Issue Supplement_1, November 2025, ehaf784.1226 

Machado FC, Coninx  K, Neunhaeuserer D, Tonoli C, Niebauer J, Piepoli M , Pedretti R, Kouidi E, Ambrosetti M, Dendale P, Bjarnason-Wehrens B, Beckers P, Cornelissen V, Barna O, Doherty P, Rauch B, Edelmann F, Schwaab B, Takken T, Reibis R, Hansen D et al. Tailored Exercise Prescription for People with COPD and Clinically Relevant Comorbidities: A Consensus Statement of the EXPERT Working Group and Experts in Pulmonary Rehabilitation. Sports Med 2025 Dec 4. doi: 10.1007/s40279-025-02353-9. Online ahead of print.

2024

Zeymer U, Goss F, Kunadt M, Oldenburg D, Hochadel M, Thiele H, Werdan K; GULLIVE-R Investigators  Patient knowledge about risk factors, achievement of target values, and guideline-adherent secondary prevention therapies 12 months after acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2024 Jul 24;13:537-545.

Podcasts

Ozempic, Wegovy und Monjaro: Gamechanger gegen Herzinfarkt? | Expertenrunde Dr. Heart

Folge 1: Nieren unter Druck – Ganz Schön Niere | RTL+

Conference Contributions

2026

Reibis RK. Leitlinie klar – Umsetzung unzureichend: SGLT2i und NT-proBNP-Bestimmung zu selten eingesetzt. 92. DGK-Jahrestagung, Mannheim, April 2026.

Abstractpreis „Kardiovaskuläre Versorgungsforschung in Deutschland 2026“ anlässlich der 92. DGK-Jahrestagung 2026.

Abstract: „Versorgungsdiskrepanz bei der Behandlung des kardiorenal-metabolischen Syndroms: Real-World-Analyse der SGLT2-Inhibitor-Nutzung bei Herzinsuffizienz, chronischer Nierenkrankheit und Typ-2-Diabetes“.

2025

Waßmann S, Reibis RK, Smetak N, Rödicker F, Ziegler E, Celer T, Lüdde M. Versorgungsrealität der chronischen Herzinsuffizienz in der deutschen Primärversorgung: Prävalenz, Diagnostik und leitlinienbasierte Therapie auf Basis von Real-World Daten. 91. DGK-Jahrestagung, Mannheim, April 2025. 

Photo: private